Traditional Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure and preparation method thereof

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure and a preparation method thereof. The traditional Chinese medicine composition for treating maintenance hemodialysis complicated by heart failure is prepared from the following raw materials in parts by mass: 25-40 parts of astragalus membranaceus, 13-20 parts of codonopsis pilosula, 8-12 parts of roasted rhizoma atractylodis macrocephalae, 8-12 parts of cimicifugae foetidae, 8-12 parts of radix puerariae, 13-20 parts of angelica sinensis, 8-12 parts of radix bupleuri, 8-12 parts of radix ophiopogonis, 8-12 parts of schisandra chinensis, 8-12 parts of pericarpium citri reticulatae, 13-60 parts of salvia miltiorrhiza, 8-40 parts of safflower carthamus and 8-12 parts of honey-fried licorice root. According to the traditional Chinese medicine composition disclosed by the invention, all the raw materials are coordinated and matched, so that the traditional Chinese medicine composition has better effects of tonifying primordial qi (namely tonifying deficiency of the heart, the liver, the spleen and the kidney) and ascending lucid yang (namely promoting diuresis, dissolving turbidity and removing stasis), can remarkably improve myocardial injury, uremic toxin and microinflammation states of a simulated maintenance hemodialysis heart failure mechanism rat disease combination model, and is strong in medicine effect and free of obvious toxic and side effects.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure and a preparation method thereof. Background Art

[0002] Maintenance hemodialysis (MHD) is the main alternative therapy for patients with end-stage renal disease (ESRD). While improving the survival rate and quality of life of patients, it also leads to a series of complications. Heart failure is the second largest cardiovascular complication in patients with maintenance hemodialysis, with an incidence rate of more than 40%, a potential risk of up to 71.5%-93.75%, and a mortality rate of nearly 50%. Refractory moderate to severe heart failure is common in clinical practice, and many patients fall into a vicious cycle. Heart failure has a high incidence rate and great harm. There is currently no effective intervention measure, and symptoms can only be improved through comprehensive diagnosis and treatment. In terms of drug treatment: Western medicine treatment only includes sacubitril-valsartan tablets, beta-blockers, and xinhuosu (but the use of xinhuosu will increase the patient's fluid intake, increase the patient's volume load, and increase the patient's heart failure factors), but the efficacy is poor; Chinese medicine treatment only includes one journal article on Xinbao Granule (Ni John et al.; Journal article; Analysis of TCM Syndrome in Patients with Uremic Cardiomyopathy Under Maintenance Hemodialysis and the Efficacy of Xinbao Granule) and one master's degree thesis on Shenlong Tongmai Pill (Tao Jing; Master's thesis; Clinical Observation of Shenlong Tongmai Pill Combined with Western Medicine in the Treatment of Maintenance Hemodialysis Heart Failure), but it is only a clinical efficacy observation, and the research depth and efficacy are limited. In summary, the clinical efficacy of maintenance hemodialysis heart failure is poor, and patients often suffer from refractory moderate to severe heart failure, repeated hospitalization and treatment but with little effect, and the prognosis is extremely poor.

[0003] In view of this, the present invention is proposed. Summary of the invention

[0004] One object of the present invention is to provide a Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, so as to solve the technical problems in the prior art that the clinical efficacy of treating maintenance hemodialysis heart failure is poor, patients often suffer from refractory moderate to severe heart failure, repeated hospitalization and treatment but with little effect, and extremely poor prognosis; the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure of the present invention has various raw materials coordinated and matched, has better effects of nourishing the heart, liver, spleen and kidney deficiency, removing dampness, removing turbidity and relieving blood stasis, can significantly improve the myocardial injury, uremic toxins and micro-inflammatory state of the symptom combination model of rats simulating the mechanism of maintenance hemodialysis heart failure, has strong efficacy, and has no obvious toxic and side effects.

[0005] Another object of the present invention is to provide a method for preparing the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, which method is simple and easy to implement.

[0006] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0007] A Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, prepared from the following raw materials in parts by weight:

[0008] 25-40 parts of Astragalus, 13-20 parts of Codonopsis, 8-12 parts of stir-fried Atractylodes, 8-12 parts of Cimicifuga, 8-12 parts of Pueraria, 13-20 parts of Angelica, 8-12 parts of Bupleurum, 8-12 parts of Ophiopogon, 8-12 parts of Schisandra, 8-12 parts of Tangerine Peel, 13-60 parts of Salvia, 8-40 parts of Safflower and 8-12 parts of Roasted Licorice.

[0009] In some embodiments, the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure is prepared from the following raw materials in parts by weight:

[0010] 28-35 parts of Astragalus, 13-18 parts of Codonopsis, 9-11 parts of stir-fried Atractylodes, 9-11 parts of Cimicifuga, 9-11 parts of Pueraria, 13-18 parts of Angelica, 9-11 parts of Bupleurum, 9-11 parts of Ophiopogon, 9-11 parts of Schisandra, 9-11 parts of Tangerine Peel, 14-18 parts of Salvia, 9-11 parts of Carthamus and 9-11 parts of Roasted Licorice.

[0011] In some embodiments, the mass ratio of the Salvia miltiorrhiza to the Carthamus tinctorius is 1.4 to 1.7.

[0012] In some embodiments, the mass ratio of the astragalus to the codonopsis is 1.8 to 2.5.

[0013] In some embodiments, the mass ratio of stir-fried Atractylodes macrocephala, Cimicifuga heracleifolia, Pueraria root, Bupleurum chinense, Ophiopogon japonicus, Schisandra chinensis, Tangerine peel, Carthamus tinctorius and roasted Licorice root is (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1).

[0014] In some embodiments, the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure is prepared from the following raw materials in parts by weight:

[0015] 30 parts of Astragalus, 15 parts of Codonopsis, 10 parts of stir-fried Atractylodes, 10 parts of Cimicifuga, 10 parts of Pueraria, 15 parts of Angelica, 10 parts of Bupleurum, 10 parts of Ophiopogon, 10 parts of Schisandra, 10 parts of Tangerine Peel, 15 parts of Salvia, 10 parts of Carthamus and 10 parts of Radix Glycyrrhizae.

[0016] In some embodiments, the dosage form of the Chinese medicine composition includes at least one of a decoction, a granule, a pill, an ointment, a powder and a pill.

[0017] The method for preparing the above-mentioned Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure comprises the following steps:

[0018] The mixture of the raw materials is decocted in water to obtain a decoction.

[0019] In some embodiments, the water decoction specifically includes: mixing the mixture of the raw materials with water, making the water higher than the mixture by 1 to 2 cm, and then performing a first decoction and a second decoction, wherein the first decoction and the second decoction obtain 180 to 250 mL of decoction liquid respectively.

[0020] In some implementations, the boiling time of the first decoction is 25 to 40 minutes, and the boiling time of the second decoction is 15 to 25 minutes.

[0021] In some embodiments, the mixture of the raw materials is immersed in water before decocting, the time of the immersion is 30 to 60 minutes, and the water level is 2 to 3.5 cm higher than the mixture.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] (1) In the Chinese medicine composition of the present invention, Astragalus has the effects of invigorating qi and raising yang, strengthening the body's defense system, promoting toxins and promoting tissue regeneration, and promoting diuresis and reducing swelling; Codonopsis has the effects of invigorating the middle and replenishing qi, strengthening the spleen and lungs; Stir-fried Atractylodes has the effects of harmonizing the middle and replenishing qi, removing dampness and heat from the spleen and stomach, strengthening the spleen and removing dampness, relieving cough, promoting urination, and enhancing the body's immunity; Cimicifuga has the effects of dispelling wind and clearing away rashes, clearing away heat and detoxifying, and raising yang and lifting sunken; Pueraria has the effects of dispelling wind and clearing rashes, protecting the liver, stabilizing blood sugar, and enhancing immunity; Bupleurum has the effects of harmonizing the exterior and interior, soothing the liver and relieving depression, The effect of raising yang and lifting the sunken; Angelica has the effects of nourishing blood, anti-inflammatory and sterilizing, promoting blood circulation and removing blood stasis; Ophiopogon has the effects of nourishing yin and clearing heat, benefiting the stomach and promoting the production of body fluid, protecting the myocardium, resisting aging and anti-tumor; Schisandra has the effects of nourishing the kidney and promoting the production of body fluid, collecting sweat and astringing essence, relieving thirst and relieving cough; Tangerine peel has the effects of regulating qi and strengthening the spleen, drying dampness and resolving phlegm; Salvia miltiorrhiza has the effects of promoting blood circulation and unblocking collaterals, removing blood stasis and relieving pain, cooling blood and eliminating carbuncle, and clearing the heart and calming the mind; Carthamus has the effects of promoting blood circulation and dredge meridians, removing blood stasis and relieving pain; Radix Glycyrrhizae Preparata has the effects of tonifying spleen and stomach, and replenishing qi and restoring pulse. The above-mentioned raw materials of the present invention are coordinated and coordinated, and have the effects of better replenishing vital energy (i.e., replenishing the deficiency of the heart, liver, spleen and kidney), raising clear yang (i.e., removing dampness, removing turbidity and removing blood stasis), and on the basis of treating from deficiency, highlighting the treatment from blood stasis, can significantly improve the myocardial injury, uremic toxins and micro-inflammatory state of the disease combination model of simulated maintenance hemodialysis heart failure mechanism rats, strong drug efficacy, and no obvious toxic and side effects.

[0024] (2) The preparation method of the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure of the present invention is simple and easy. The obtained Chinese medicine composition has good effects of invigorating the stomach and promoting body fluid, protecting the myocardium, resisting inflammation and toxins, and improving immunity. It can significantly improve the myocardial injury, uremic toxins and micro-inflammatory state of the combined model of symptoms of rats simulating the mechanism of maintenance hemodialysis heart failure. It has strong efficacy and no obvious toxic and side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0026] Figure 1 It is the normal distribution curve of the number of deaths of rats in each group changing with time;

[0027] Figure 2 The comparison chart of body weight of rats in each group at the end of each week;

[0028] Figure 3 This is a comparison chart of BUN in each group of rats at the end of each week;

[0029] Figure 4 Comparison of HE staining light microscopy and transmission electron microscopy of myocardium of rats in each group;

[0030] Figure 5 This is a comparison chart of the RT-PCR detection results of the P13K-AKT-mTOR pathway in rats in each group. DETAILED DESCRIPTION

[0031] The embodiments of the present invention will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0032] According to one aspect of the present invention, the present invention relates to a Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, which is prepared from the following raw materials in parts by weight:

[0033] 25-40 parts of Astragalus, 13-20 parts of Codonopsis, 8-12 parts of stir-fried Atractylodes, 8-12 parts of Cimicifuga, 8-12 parts of Pueraria, 13-20 parts of Angelica, 8-12 parts of Bupleurum, 8-12 parts of Ophiopogon, 8-12 parts of Schisandra, 8-12 parts of Tangerine Peel, 13-60 parts of Salvia, 8-40 parts of Safflower and 8-12 parts of Roasted Licorice.

[0034] In the Chinese medicine composition of the present invention, Astragalus belongs to the spleen and lung meridians, and has the effects of invigorating qi and raising yang, benefiting the body's defense system and strengthening the exterior, expelling toxins and promoting tissue regeneration, and promoting diuresis and reducing swelling; Codonopsis belongs to the spleen and lung meridians, and has the effects of invigorating the middle and replenishing qi, strengthening the spleen and benefiting the lungs; Stir-fried Atractylodes macrocephala has the effects of harmonizing the middle and replenishing qi, removing damp-heat from the spleen and stomach, strengthening the spleen and removing dampness, relieving cough, promoting urination, and enhancing the body's immunity; Cimicifuga heracleifolia has the effects of dispelling wind and clearing away rashes, clearing away heat and detoxifying, and raising yang and lifting sunken; Pueraria root has the effects of dispelling wind and clearing rashes, protecting the liver, stabilizing blood sugar, and enhancing immunity; Bupleurum has the effects of harmonizing the exterior and interior, The effects of soothing the liver and relieving depression, raising yang and lifting the sunken; Angelica has the effects of nourishing blood, anti-inflammatory and sterilizing, promoting blood circulation and removing blood stasis; Ophiopogon has the effects of nourishing yin and clearing heat, benefiting the stomach and promoting the production of body fluid, protecting the myocardium, resisting aging and anti-tumor; Schisandra has the effects of nourishing the kidney and promoting the production of body fluid, collecting sweat and astringing essence, relieving thirst and relieving cough; Tangerine peel has the effects of regulating qi and strengthening the spleen, drying dampness and resolving phlegm; Salvia miltiorrhiza has the effects of promoting blood circulation and unblocking collaterals, removing stasis and relieving pain, cooling blood and eliminating carbuncle, and clearing the heart and calming the mind; Carthamus has the effects of promoting blood circulation and dredge meridians, removing stasis and relieving pain; Radix Glycyrrhizae Preparata has the effects of tonifying the spleen and stomach, and replenishing qi and restoring pulse. The above-mentioned raw materials of the present invention are coordinated and coordinated, and have the effects of better replenishing vital energy (i.e., replenishing the deficiency of the heart, liver, spleen and kidney), raising the clear yang (i.e., removing dampness, removing turbidity and removing blood stasis), and on the basis of treating from deficiency, highlighting the treatment from stasis, can significantly improve the myocardial injury, uremic toxins and micro-inflammatory state of the disease combination model of simulated maintenance hemodialysis heart failure mechanism rats, strong drug efficacy, and no obvious toxic and side effects. This Chinese medicine combination is a perfect display of the "differential diagnosis view" and "holistic view" of traditional Chinese medicine, and is also a model of the Chinese medicine prescriptions of "one prescription for multiple functions", "different diseases with the same treatment", and "different syndromes with the same treatment".

[0035] In some embodiments, the amount of Astragalus membranaceus is 25 to 40 parts by weight, such as 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, 31 parts, 32 parts, 33 parts, 34 parts, 35 parts, 36 parts, 38 parts, 39 parts or 40 parts, or any range between the two. Astragalus membranaceus is sweet and warm, and it belongs to the spleen and lung meridians. It has the effects of invigorating qi and raising yang, benefiting the body's defense and strengthening the exterior, supporting poison and promoting muscle growth, and promoting diuresis and reducing swelling. It can be used to treat the symptoms of spleen and lung qi deficiency and the sinking of middle qi, and can be used to treat qi deficiency and blood deficiency, qi deficiency and blood loss, and qi deficiency and blood stasis. Astragalus membranaceus with an appropriate dosage ratio, coordinated with other raw materials, can effectively treat myocardial damage, uremic toxins and micro-inflammation caused by maintenance hemodialysis.

[0036] In some embodiments, by weight, Codonopsis is 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, etc., or any range value between the two. Codonopsis is flat in nature, sweet and slightly sour, and it belongs to the spleen and lung meridians. It replenishes the middle qi, strengthens the spleen and lungs; it is used for spleen and lung weakness, shortness of breath and palpitations, poor appetite and loose stools, asthenia and cough, internal heat and thirst; it can enhance the body's resistance, lower blood pressure, replenish the spleen and lungs, and nourish blood. It is rich in polysaccharides, vitamins, amino acids, trace elements, and has high nutritional value. An appropriate amount of Codonopsis coordinates with other components, which is more conducive to improving the spleen and lung nourishing and blood nourishing effects of the Chinese medicine composition, and improving the effect of resistance.

[0037] In some embodiments, the stir-fried Atractylodes macrocephala is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc., or any range value between the two parts, by weight. Stir-fried Atractylodes macrocephala has the effects of harmonizing the middle qi, removing dampness and heat from the spleen and stomach, strengthening the spleen and removing dampness, relieving cough, and diuresis. It can also resist gastric ulcers and enhance body immunity. Suitable stir-fried Atractylodes macrocephala is combined with other raw material components to be more conducive to improving the spleen and stomach tonifying effect of the Chinese medicine composition, and is conducive to improving the body's resistance.

[0038] In some embodiments, the amount of Cimicifuga is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc., or any range between the two parts, by weight. Efficacy of Cimicifuga: relieving rash, clearing away heat and detoxifying, and raising yang and lifting sunken. An appropriate amount of Cimicifuga can be combined with Astragalus, Pueraria, and Bupleurum to treat the root of qi deficiency, lift the sunken clear yang, take into account both the symptoms and the root cause, replenish the middle qi, and lift it effectively.

[0039] In some embodiments, the kudzu root is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc., or any range value between the two parts by mass. The kudzu root has the effects of relieving the symptoms and clearing the rash, protecting the liver, stabilizing blood sugar, resisting fatigue, enhancing immunity, and regulating endocrine. The Chinese medicine composition of the present invention adopts suitable kudzu root, and cooperates with other raw materials to help improve the effect of protecting the liver and improve the body's immunity.

[0040] In some embodiments, by weight, bupleurum is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc., or any range between the two. Bupleurum has the effects of reconciling the exterior and interior, soothing the liver and relieving depression, raising yang and lifting depression, and relieving fever and stopping malaria. An appropriate amount of bupleurum is combined with other raw materials to improve the effect of raising yang and lifting depression of the traditional Chinese medicine composition.

[0041] In some embodiments, the amount of angelica is 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, etc., or any range value between the two parts by weight. Angelica has the effects of nourishing blood, reducing inflammation and killing bacteria, promoting blood circulation and removing blood stasis, and improving immunity. An appropriate amount of angelica is coordinated with other raw material components to be more conducive to improving the anti-inflammatory and blood circulation and blood stasis effects of the Chinese medicine composition.

[0042] In some embodiments, the amount of Ophiopogon japonicus is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc., or any range value between the two parts, by weight. Ophiopogon japonicus has the effects of nourishing yin and clearing away heat, benefiting the stomach and promoting the production of body fluid, moistening the intestines and relieving constipation, protecting the myocardium, resisting aging, resisting tumors, and improving immunity. The present invention adopts an appropriate amount of Ophiopogon japonicus in combination with other raw material components, which is more conducive to improving the effects of benefiting the stomach and promoting the production of body fluid, protecting the myocardium, and improving immunity of the Chinese medicine composition.

[0043] In some embodiments, the amount of Schisandra chinensis is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc., or any range between the two parts, by weight. Schisandra chinensis has the effects of nourishing the kidney and promoting body fluid, collecting sweat and astringing essence, relieving thirst and relieving cough; it has the effects of protecting the liver and improving immunity. The present invention adopts suitable Schisandra chinensis to cooperate with other raw material components, which is conducive to improving the effect of protecting the liver of the Chinese medicine composition.

[0044] In some embodiments, in parts by mass, dried tangerine peel is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc., or any range value between the two. Dried tangerine peel has the effects of regulating qi and strengthening the spleen, drying dampness and resolving phlegm. The present invention adopts an appropriate amount of dried tangerine peel coordinated with other components to improve the anti-inflammatory effect of the Chinese medicine composition.

[0045] In some embodiments, by mass fraction, Danshen is 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 25 parts, 30 parts, 40 parts, 50 parts or 60 parts, or any range value between the two. Danshen is bitter, slightly cold, and enters the heart and liver meridians. It has the effects of promoting blood circulation and dredging collaterals, removing stasis and relieving pain, cooling blood and eliminating carbuncle, and clearing the heart and calming the mind. The present invention adopts Danshen in an appropriate amount, and the coordination and cooperation with other components can improve the effect of improving cardiac function and microcirculation of the Chinese medicine composition.

[0046] In some embodiments, the amount of safflower is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, 15 parts, 20 parts, 25 parts, 30 parts, 35 parts or 40 parts, or any range value between the two parts, by weight. Safflower has the effects of promoting blood circulation, relieving menstruation, removing blood stasis and relieving pain. The present invention adopts an appropriate amount of safflower, in combination with other raw material components, which is conducive to improving the effects of the Chinese medicine composition in protecting cardiovascular, improving microcirculation, and anti-inflammatory and analgesic.

[0047] In some embodiments, the amount of licorice root is 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, etc., or any range value between the two parts, by weight. Licorice root has the effects of tonifying the spleen and stomach, invigorating qi and restoring pulse, clearing away heat and detoxifying, anti-inflammatory, antiviral, and anti-oxidation. The present invention adopts a suitable amount of licorice root, in combination with other raw material components, which is conducive to improving the qi-tonifying spleen and anti-inflammatory effects of the Chinese medicine composition.

[0048] In some embodiments, the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure is prepared from the following raw materials in parts by weight:

[0049] 28-35 parts of Astragalus, 13-18 parts of Codonopsis, 9-11 parts of stir-fried Atractylodes, 9-11 parts of Cimicifuga, 9-11 parts of Pueraria, 13-18 parts of Angelica, 9-11 parts of Bupleurum, 9-11 parts of Ophiopogon, 9-11 parts of Schisandra, 9-11 parts of Tangerine Peel, 14-18 parts of Salvia, 9-11 parts of Carthamus and 9-11 parts of Roasted Licorice.

[0050] By further optimizing the dosage ratio of each raw material, it is more conducive to exerting the coordinated and cooperative effect of each raw material, so as to improve the effects of the Chinese medicine composition on benefiting the stomach and promoting fluid production, protecting the myocardium, resisting inflammation and toxins, and improving immunity, and thus can effectively treat myocardial damage, uremic toxins and micro-inflammation caused by maintenance hemodialysis.

[0051] In some embodiments, the mass ratio of the Salvia miltiorrhiza to the Carthamus tinctorius is 1.4 to 1.7, such as 1.4, 1.5, 1.6 or 1.7.

[0052] In some embodiments, the mass ratio of the astragalus to the codonopsis is 1.8-2.5, for example, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.5, etc.

[0053] In some embodiments, the mass ratio of the stir-fried Atractylodes macrocephala, Cimicifuga heracleifolia, Pueraria root, Bupleurum root, Ophiopogon japonicus, Schisandra chinensis, Tangerine peel, Carthamus tinctorius and Radix Glycyrrhizae is (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1). In some embodiments, the mass of the stir-fried Atractylodes macrocephala, Cimicifuga heracleifolia, Pueraria root, Bupleurum root, Ophiopogon japonicus, Schisandra chinensis, Tangerine peel, Carthamus tinctorius and Radix Glycyrrhizae is equal.

[0054] In some embodiments, the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure is prepared from the following raw materials in parts by weight:

[0055] 30 parts of Astragalus, 15 parts of Codonopsis, 10 parts of stir-fried Atractylodes, 10 parts of Cimicifuga, 10 parts of Pueraria, 15 parts of Angelica, 10 parts of Bupleurum, 10 parts of Ophiopogon, 10 parts of Schisandra, 10 parts of Tangerine Peel, 15 parts of Salvia, 10 parts of Carthamus and 10 parts of Radix Glycyrrhizae.

[0056] In some embodiments, the traditional Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure is prepared from the following raw materials of mass: 30g of Astragalus, 15g of Codonopsis, 10g of stir-fried Atractylodes, 10g of Cimicifuga, 10g of Pueraria, 15g of Angelica, 10g of Bupleurum, 10g of Ophiopogon, 10g of Schisandra, 10g of Tangerine Peel, 15g of Salvia, 10g of Carthamus and 10g of Radix Glycyrrhizae.

[0057] In some embodiments, the dosage form of the Chinese medicine composition includes at least one of a decoction, a granule, a pill, an ointment, a powder, and a pill. The Chinese medicine composition of the present invention may include the above-mentioned various dosage forms.

[0058] According to another aspect of the present invention, the present invention also relates to a method for preparing the above-mentioned Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, comprising the following steps:

[0059] The mixture of the raw materials is decocted in water to obtain a decoction.

[0060] The preparation method of the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure of the present invention is simple and easy. The obtained Chinese medicine composition has good effects of invigorating the stomach and promoting body fluid, protecting the myocardium, resisting inflammation and toxins, and improving immunity. It can significantly improve the myocardial injury, uremic toxins and micro-inflammatory state of the symptom combination model of rats simulating the mechanism of maintenance hemodialysis heart failure, has strong efficacy, and has no obvious toxic and side effects.

[0061] In some embodiments, the decoction specifically includes: mixing the mixture of each raw material with water, making the water 1 to 2 cm higher than the mixture, and then performing a first decoction and a second decoction, wherein the first decoction and the second decoction obtain 180 to 250 mL of decoction respectively. The boiling time of the first decoction is 25 to 40 minutes, and the boiling time of the second decoction is 15 to 25 minutes. By adopting appropriate decoction conditions, the active ingredients in each raw material are ensured, thereby obtaining a Chinese medicine composition of appropriate concentration.

[0062] In some embodiments, the mixture of the raw materials is soaked in water before decocting, and the soaking time is 30 to 60 minutes, and the water level is 2 to 3.5 cm higher than the mixture. The soaking can improve the efficacy of traditional Chinese medicine and make it easier to boil out the active ingredients during the decoction process.

[0063] In some implementations, the best medicine decoction container is a casserole, followed by an enamelware container.

[0064] The following is further explained in conjunction with specific embodiments and comparative examples.

[0065] Example 1

[0066] A Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, prepared from the following raw materials in parts by weight:

[0067] 30 parts of Astragalus, 15 parts of Codonopsis, 10 parts of stir-fried Atractylodes, 10 parts of Cimicifuga, 10 parts of Pueraria, 15 parts of Angelica, 10 parts of Bupleurum, 10 parts of Ophiopogon, 10 parts of Schisandra, 10 parts of Tangerine Peel, 15 parts of Salvia, 10 parts of Carthamus and 10 parts of Radix Glycyrrhizae.

[0068] A method for preparing a Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure comprises the following steps:

[0069] (1) The mixture of the raw materials is subjected to water immersion treatment for 50 minutes, and the water level is 3 cm higher than the mixture.

[0070] (2) mixing the mixture of the raw materials after the water immersion treatment in step (1) with water so that the water is 1.5 cm higher than the mixture, performing the first decoction, boiling and then decocting for 30 minutes, and pouring out 200 mL of the medicinal liquid after the first decoction is completed; adding clean water for the second decoction so that the water is 1 cm higher than the mixture, boiling the second decoction for 20 minutes, and pouring out 200 mL of the medicinal liquid after the second decoction is completed, and combining the two medicinal liquids and packaging them.

[0071] Example 2

[0072] A Chinese medicine composition is prepared from the following raw materials in parts by weight:

[0073] 30 parts of Astragalus, 15 parts of Codonopsis, 10 parts of stir-fried Atractylodes, 10 parts of Cimicifuga, 10 parts of Pueraria, 15 parts of Angelica, 10 parts of Bupleurum, 10 parts of Ophiopogon, 10 parts of Schisandra, 10 parts of Tangerine Peel, 30 parts of Salvia, 20 parts of Carthamus and 10 parts of Roasted Licorice.

[0074] The preparation method of the Chinese medicine composition of this embodiment is the same as that of Example 1 except that the raw materials of the above-mentioned mass fractions are used.

[0075] Example 3

[0076] A Chinese medicine composition is prepared from the following raw materials in parts by weight:

[0077] 30 parts of Astragalus, 15 parts of Codonopsis, 10 parts of stir-fried Atractylodes, 10 parts of Cimicifuga, 10 parts of Pueraria, 15 parts of Angelica, 10 parts of Bupleurum, 10 parts of Ophiopogon, 10 parts of Schisandra, 10 parts of Tangerine Peel, 60 parts of Salvia, 40 parts of Carthamus and 10 parts of Radix Glycyrrhizae.

[0078] The preparation method of the Chinese medicine composition of this embodiment is the same as that of Example 1 except that the raw materials of the above-mentioned mass fractions are used.

[0079] Example 4

[0080] A Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, prepared from the following raw materials in parts by weight:

[0081] 28 parts of Astragalus, 13 parts of Codonopsis, 9 parts of Rhizoma Atractylodis Macrocephalae, 9 parts of Cimicifuga, 9 parts of Radix Puerariae, 13 parts of Radix Angelicae Sinensis, 9 parts of Radix Bupleuri, 9 parts of Radix Ophiopogonis, 9 parts of Fructus Schisandrae Chinensis, 9 parts of Pericarpium Citri Reticulatae, 14 parts of Radix Salviae Miltiorrhizae, 9 parts of Carthamus tinctorius, and 9 parts of Radix Glycyrrhizae Preparata. The preparation method of the Chinese medicine composition for treating heart failure complicated by maintenance hemodialysis is the same as that of Example 1 except that the raw materials of the above mass parts are used.

[0082] Example 5

[0083] A Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, prepared from the following raw materials in parts by weight:

[0084] 35 parts of Astragalus, 18 parts of Codonopsis, 11 parts of stir-fried Atractylodes, 11 parts of Cimicifuga, 11 parts of Pueraria, 18 parts of Angelica, 11 parts of Bupleurum, 11 parts of Ophiopogon, 11 parts of Schisandra, 11 parts of Tangerine Peel, 18 parts of Salvia, 11 parts of Carthamus and 11 parts of Radix Glycyrrhizae.

[0085] The method for preparing the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure is the same as that in Example 1 except that the above-mentioned raw materials in parts by mass are used.

[0086] Example 6

[0087] A Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, prepared from the following raw materials in parts by weight:

[0088] 40 parts of Astragalus, 20 parts of Codonopsis, 12 parts of stir-fried Atractylodes, 12 parts of Cimicifuga, 12 parts of Pueraria, 20 parts of Angelica, 12 parts of Bupleurum, 12 parts of Ophiopogon, 12 parts of Schisandra, 12 parts of Tangerine Peel, 20 parts of Salvia, 12 parts of Carthamus and 12 parts of Radix Glycyrrhizae.

[0089] A method for preparing a Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure comprises the following steps:

[0090] (1) The mixture of the raw materials is subjected to water immersion treatment for 30 minutes, and the water level is 3.5 cm higher than the mixture.

[0091] (2) Mix the mixture of the raw materials after the water immersion treatment in step (1) with water so that the water is 2 cm higher than the mixture, and then perform the first decoction. After the first boiling, boil for another 30 minutes. After the first decoction is completed, pour out 200 mL of the medicinal liquid. Add clean water and perform the second decoction. The boiling time of the second decoction is 20 minutes. After the second decoction is completed, pour out 200 mL of the medicinal liquid. The two medicinal liquids are combined and packaged.

[0092] Example 7

[0093] A Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, prepared from the following raw materials in parts by weight:

[0094] 25 parts of Astragalus, 13 parts of Codonopsis, 8 parts of stir-fried Atractylodes, 8 parts of Cimicifuga, 8 parts of Pueraria, 13 parts of Angelica, 8 parts of Bupleurum, 8 parts of Ophiopogon, 8 parts of Schisandra, 8 parts of Tangerine Peel, 13 parts of Salvia, 8 parts of Carthamus and 8 parts of Radix Glycyrrhizae.

[0095] A method for preparing a Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure comprises the following steps:

[0096] (1) The mixture of the raw materials is subjected to water immersion treatment for 60 minutes, and the water level is 2 cm higher than the mixture.

[0097] (2) Mixing the mixture of the raw materials after the water immersion treatment in step (1) with water so that the water is 1 cm higher than the mixture, and then performing the first decoction. After the first boiling, the mixture is boiled for another 30 minutes. After the first decoction is completed, 200 mL of the medicinal liquid is poured out. After adding clean water, the second decoction is performed. The boiling time of the second decoction is 20 minutes. After the second decoction is completed, 200 mL of the medicinal liquid is poured out. The two medicinal liquids are combined and packaged.

[0098] Comparative Example 1

[0099] A Chinese medicine composition is prepared from the following raw materials in parts by weight:

[0100] 30 parts of Astragalus, 15 parts of Codonopsis, 10 parts of stir-fried Atractylodes, 10 parts of Cimicifuga, 10 parts of Pueraria, 15 parts of Angelica, 10 parts of Bupleurum, 10 parts of Ophiopogon, 10 parts of Schisandra, 10 parts of Tangerine Peel and 10 parts of Roasted Licorice.

[0101] The preparation method of the Chinese medicine composition of this comparative example is the same as that of Example 1 except that the above-mentioned raw materials in parts by mass are used.

[0102] Experimental example

[0103] Each group of rats was gavaged with adenine edible oil solution, intraperitoneally injected with doxorubicin, and potassium bromate solution was used instead of drinking water to build a model of heart failure (HF) in a rat model simulating maintenance hemodialysis (MHD). At the end of the first week of modeling, when creatinine (Cr) increased to 1.5 times, a Chinese medicine composition was gavaged.

[0104] Each group of rats was given the Chinese medicine composition of the embodiment and the comparative example by regular gavage. Among them, the dosage of embodiment 1 (group 1) was 17.325 g crude drug / kg, the dosage of comparative example 1 (group 0) was 14.7 g crude drug / kg, the dosage of embodiment 2 (group 2) was 19.95 g crude drug / kg, and the dosage of embodiment 3 (group 3) was 25.2 g crude drug / kg, with a frequency of 1 time / day for 6 weeks.

[0105] The modeling group received simple modeling as a control.

[0106] Observe general conditions at the end of every week, and record body weight and food intake. In terms of Western medicine diseases: measure renal function [urea nitrogen (BUN), Cr] every weekend. Measure C-reactive protein (CRP), blood pressure, heart rate (HR), echocardiogram [left ventricular ejection fraction (LVEF), shortening fraction (FS), etc.] at the end of 6 weeks; calculate the total heart mass index (HM / BM) and left ventricular mass index (LVM / BM); observe myocardial pathology in each group by light microscopy and transmission electron microscopy; mRNA expression levels of key genes in the PI3K-AKT pathway (PI3K, AKT, mTORC1). In terms of TCM syndromes: compare the quantitative scores of TCM syndromes among the groups, and perform grip strength tests and treadmill experiments at the end of 6 weeks. The specific effects are as follows:

[0107] 1. Death rate in each group

[0108] Total mortality rate: Modeling group 50% > Group 0 45% > Group 2 40% = Group 3 40% > Group 1 30%. The normal distribution curve of the number of deaths of rats in each group over time is shown in the figure below. Figure 1 shown.

[0109] Distribution of death time: The mortality rate was highest at the end of the fourth week in each group. The death frequency was normally distributed, and there was no statistical difference between the groups. Figure 1 shown.

[0110] 2. General situation of each group

[0111] The rats in the modeling group gradually developed mental depression, slow reaction, dull fur, loose stools, dark red and swollen tongue, congestion at the end of the nail bed, abdominal swelling and hair loss, etc.; the general conditions of the examples and comparative examples were improved (mental and reaction states were improved, stools were basically formed, and the tongue was dark red and not swollen), among which Group 1 had the best effect compared with the other groups. The body weight of the examples and comparative example groups increased, and there were statistical differences since the fourth weekend, and the value of Group 1 was the highest at the sixth weekend. The food intake of the examples and comparative example groups increased, and there were statistical differences since the third weekend, and the value of Group 1 was the highest at the sixth weekend. The body weight comparison of rats in each group at the end of each week is shown in the figure below. Figure 2 Note: Compared with the modeling group, *P<0.05, **P<0.01; compared with group 0, #P<0.05, ##P<0.01; compared with group 1, ▲P<0.05, ▲▲P<0.01; compared with group 2, AP<0.05, △AP<0.01; compared with group 3, %P<0.05, %%P<0.01.

[0112] The comparison of food intake is shown in Table 1.

[0113] Table 1 Comparison of weekly food intake of rats in each group

[0114]

[0115] Note: Compared with the modeling group, * P<0.05, ** P<0.01; compared with group 0, # P<0.05, ## P<0.01; compared with group 1, ▲▲ P<0.01; compared with group 2, Δ P<0.05, ΔΔ P<0.01; compared with group 3, ％ P<0.05, ％％ P<0.01.

[0116] 3. Western medicine diseases

[0117] (1) Renal function test results

[0118] The BUN and Cr of each embodiment and comparative example group decreased, and there were statistical differences from the 3rd and 5th weekends, respectively. The value of group 1 was the lowest at the 6th weekend. Figure 3As shown, Note: Compared with the modeling group, **P<0.01; compared with group 0, #P<0.05, ##P<0.01; compared with group 1, ▲P<0.05, ▲▲P<0.01.

[0119] The Cr comparison results are shown in Table 2.

[0120] Table 2 Comparison of Cr in each group of rats at the end of each week

[0121]

[0122] Note: Compared with the modeling group, ** P<0.01; compared with group 0, ## P<0.01; compared with group 1, ▲▲ P<0.01; compared with group 2, △ P<0.05, △△ P<0.01; compared with group 3, ％ P<0.05, ％％ P<0.01.

[0123] (2) CRP test results

[0124] At the end of the sixth week, the CRP of group 0 decreased, but there was no statistical difference; the CRP of groups 1, 2, and 3 decreased significantly, with the lowest value in group 1. The CRP comparison results of rats in each group at the end of the sixth week are shown in Table 3.

[0125] Table 3 Comparison of CRP in rats of each group at the end of the sixth week

[0126]

[0127] Note: Compared with the modeling group, ** P<0.01; compared with group 0, ## P<0.01; compared with group 1, ▲▲ P<0.01; compared with group 2, △△P<0.01; compared with group 3, %%P<0.01.

[0128] (3) Blood pressure and HR test results

[0129] Except for the SBP of group 0, the SBP of other groups increased significantly, and the improvement was the best in group 1. The comparison results of blood pressure and HR of rats in each group at the end of the sixth week are shown in Table 4.

[0130] The control group refers to a blank group of rats that have not been treated in any way and is used to provide data of normal rats to compare the effects of modeling and the efficacy of the Chinese medicine composition of the present invention.

[0131] Table 4 Comparison of blood pressure and HR of rats in each group at the end of the sixth week

[0132]

[0133] Note: Compared with the control group, ●● P<0.01; compared with the model group, *P<0.05, ** P<0.01; compared with group 0, # P<0.05, ## P<0.01; compared with group 1, ▲ P<0.05, ▲▲ P<0.01; compared with group 2, Δ P<0.05, ΔΔ P<0.01; compared with group 3, ％ P<0.05, ％％ P<0.01.

[0134] (4) Echocardiography

[0135] LVEF and FS of each embodiment and comparative example group increased, and the value of group 1 was the highest. The other indicators of each compound intervention group were improved, and the improvement effect of group 1 was the best. The comparison results of echocardiogram of rats in each group at the end of the 6th week are shown in Table 5.

[0136] Table 5 Comparison of echocardiograms of rats in each group at the end of the sixth week

[0137]

[0138]

[0139] Note: Compared with the control group, ●● P<0.01; compared with the model group, **P<0.01; compared with group 0, # P<0.05, ## P<0.01; compared with group 1, ▲ P<0.05, ▲▲ P<0.01; compared with group 2, △ P<0.05, △△ P<0.01; compared with group 3, ％％ P<0.01.

[0140] (5) Heart mass index

[0141] HM / BM in each embodiment and comparative example group decreased, with group 1 being the lowest; LVM / BM in groups 1 and 3 decreased significantly, with group 1 being the lowest. The comparison of heart mass index in each group of rats at the end of the sixth week is shown in Table 6.

[0142] Table 6 Comparison of heart mass index of rats in each group at the end of the sixth week

[0143]

[0144] Note: Compared with the control group, ● P<0.05, ●● P<0.01; compared with the model group, **P<0.01; compared with group 0, ## P<0.01; compared with group 1, ▲▲ P<0.01; compared with group 3, ％％ P<0.01.

[0145] (6) Myocardial pathology

[0146] The myocardial pathology of each embodiment and comparative group was improved to a certain extent. The degree of differentiation under light microscope was relatively low, and the ultrastructure under electron microscope was relatively obvious. Comprehensive evaluation showed that the improvement effects of group 0, group 1, group 2, and group 3 were enhanced in turn. Figure 4 shown.

[0147] (7) mRNA expression levels of key genes in the PI3K-AKT pathway (PI3K, AKT, mTORC1)

[0148] The mRNA levels of (PI3K, AKT, mTORC1)-mRNA in the example group were all increased, while those in the control group were all decreased after intervention with the Chinese medicine composition of the present invention, with group 1 being the lowest. This confirms that the PI3K-AKT pathway is involved in myocardial cell autophagy in MHD-HF, and the Chinese medicine compound of the present invention can regulate the pathway, improve myocardial cell autophagy, protect the myocardium of MHD-HF, and restore its cardiac function. Figure 5 Note: Compared with the normal group, *P<0.05, **P<0.01; compared with the model group, #P<0.05, ##P<0.01.

[0149] 4. TCM Syndrome

[0150] (1) Quantitative scoring of TCM syndromes

[0151] The scores of each embodiment and comparative example group decreased every weekend, and group 1 was the lowest at the end of the sixth week. The comparison of the quantitative scores of TCM syndromes of each group of rats every weekend is shown in Table 7.

[0152] Table 7 Comparison of quantitative scores of TCM syndromes in each group of rats at the end of each week

[0153]

[0154]

[0155] Note: Compared with the modeling group, ** P<0.01; compared with group 0, # P<0.05, ## P<0.01; compared with group 1,▲ P<0.05, ▲▲ P<0.01; compared with group 2, △△ P<0.01; compared with group 3, ％％ P<0.01.

[0156] (2) Physical endurance

[0157] The gripping force of each embodiment and comparative example group increased at the end of the sixth week, with group 1 being the highest; the number of electric shocks in groups 1 and 3 at the end of the sixth week of the treadmill test was significantly reduced, with group 1 being the lowest. The comparison of the physical endurance of each group of rats at the end of the sixth week is shown in Table 8.

[0158] Table 8 Comparison of physical endurance of rats in each group at the end of the sixth week

[0159]

[0160] Note: Compared with the modeling group, ** P<0.01; compared with group 0, # P<0.05, ## P<0.01; compared with group 1, ▲▲ P<0.01; compared with group 2, △△ P<0.01; compared with group 3, ％ P<0.05.

[0161] As can be seen from the above, the present invention explores the difference in the myocardial protective effect of the Chinese medicine composition of the embodiment of the present invention and the comparative example on the combined model of symptoms of the simulated MHD-HF mechanism rat constructed by the inventor (the TCM syndrome is spleen and kidney qi deficiency, dampness turbidity and blood stasis syndrome). In view of the characteristics of MHD with heavy blood stasis, on the basis of treating from the deficiency, the treatment from the blood stasis is emphasized.

[0162] Danshen and safflower are used to promote blood circulation and remove blood stasis, and they are coordinated with other components to play a coordinated role. The research results show that: 5 The Chinese medicine composition of the present invention can significantly improve the urinary

[0163] The clinical efficacy of the present invention is poor without the addition of salvia miltiorrhiza and safflower, and their high-dose use can enhance the improvement of myocardial pathology, but other efficacy indicators decrease, indicating that simply treating the deficiency or excessive blood stasis is not appropriate; comprehensive evaluation shows that prescription No. 1 has the best efficacy.

[0164] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure, characterized in that: It is prepared from the following raw materials in parts by weight: 25-40 parts of Astragalus, 13-20 parts of Codonopsis, 8-12 parts of stir-fried Atractylodes, 8-12 parts of Cimicifuga, 8-12 parts of Pueraria, 13-20 parts of Angelica, 8-12 parts of Bupleurum, 8-12 parts of Ophiopogon, 8-12 parts of Schisandra, 8-12 parts of Tangerine Peel, 13-60 parts of Salvia, 8-40 parts of Safflower and 8-12 parts of Roasted Licorice.

2. The Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to claim 1, characterized in that: It is prepared from the following raw materials in parts by weight: 28-35 parts of Astragalus, 13-18 parts of Codonopsis, 9-11 parts of stir-fried Atractylodes, 9-11 parts of Cimicifuga, 9-11 parts of Pueraria, 13-18 parts of Angelica, 9-11 parts of Bupleurum, 9-11 parts of Ophiopogon, 9-11 parts of Schisandra, 9-11 parts of Tangerine Peel, 14-20 parts of Salvia, 9-12 parts of Carthamus and 9-11 parts of roasted Licorice.

3. The Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to claim 2, characterized in that: The mass ratio of the salvia miltiorrhiza to the safflower is 1.4 to 1.

7.

4. The Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to claim 1 or 2, characterized in that: The mass ratio of the astragalus to the codonopsis is 1.8 to 2.

5.

5. The Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to claim 2, characterized in that: The mass ratio of the stir-fried Atractylodes macrocephala, Cimicifuga heracleifolia, Pueraria root, Bupleurum chinense, Ophiopogon japonicus, Schisandra chinensis, Tangerine peel, Carthamus tinctorius and roasted Licorice root is (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1): (0.9-1).

6. The Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to claim 2, characterized in that: It is prepared from the following raw materials in parts by weight: 30 parts of Astragalus, 15 parts of Codonopsis, 10 parts of stir-fried Atractylodes, 10 parts of Cimicifuga, 10 parts of Pueraria, 15 parts of Angelica, 10 parts of Bupleurum, 10 parts of Ophiopogon, 10 parts of Schisandra, 10 parts of Tangerine Peel, 15 parts of Salvia, 10 parts of Carthamus and 10 parts of Radix Glycyrrhizae.

7. The Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to claim 1, characterized in that: The dosage form of the Chinese medicine composition includes at least one of a decoction, a granule, a pill, an ointment, a powder and a pill.

8. The method for preparing the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to any one of claims 1 to 6, characterized in that: The following steps are involved: The mixture of the raw materials is decocted in water to obtain a decoction.

9. The method for preparing the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to claim 8, characterized in that: The decoction specifically comprises: mixing the mixture of the raw materials with water, making the water higher than the mixture by 1 to 2 cm, and then performing a first decoction and a second decoction, wherein the first decoction and the second decoction respectively obtain 180 to 250 mL of decoction liquid.

10. The method for preparing the Chinese medicine composition for treating maintenance hemodialysis complicated with heart failure according to claim 9, characterized in that: The boiling time of the first decoction is 25 to 40 minutes, and the boiling time of the second decoction is 15 to 25 minutes; And / or, the mixture of the raw materials is immersed in water before decocting, the time of the immersion is 30 to 60 minutes, and the water level is 2 to 3.5 cm higher than the mixture.

Images